NURS 5334 ADVANCED PHARMACOLOGY EXAM 2 AND
PRACTICE 2026/2027 - QUESTIONS AND ANSWERS 100%
VERIFIED DETAILED RATIONALES - PASS GUARANTEED - A+
GRADED
148 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NURS 5334 ADVANCED PHARMACOLOGY EXAM 2 AND PRACTICE 2026/2027 - QUESTIONS AND
ANSWERS 100% VERIFIED DETAILED RATIONALES - PASS GUARANTEED - A+ GRADED. It contains 148
carefully selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 148 Questions
Foundations - Application - NURS 5334 Advanced Pharmacology 2 AND 2026/2027 AND 100 Detailed
Rationales PASS Guaranteed A Advanced Pharmacology Graduate Msn/dnp-level Advanced Pharmacology
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
NURS 5334 Advanced 1-25 Explains, Therapy, Chronic, Atrial Fibrillation, Heart Failure
Pharmacology 2 AND
2026/2027 AND 100 Detailed
Rationales PASS Guaranteed
A Advanced Pharmacology
Graduate Msn/dnp-level
Advanced Pharmacology
Mechanism 26-50 Explains, Appropriate, Monitoring, Inhibitors, Warfarin
Started 51-75 Explains, Mechanism, Prescribed, Develops, Property
Prescribed 76-100 Explains, Inhibitor, Pharmacodynamic, Asthma, Monitoring
Appropriate 101-125 Explains, Mechanism, Requires, Therapy, Describes
Failure 126-148 Mechanism, Explains, Heparin, Started, Reduced
TOTAL 148 All questions include answers and detailed rationales
,Section A - NURS 5334 Advanced Pharmacology 2 AND
2026/2027 AND 100 Detailed Rationales PASS Guaranteed A
Advanced Pharmacology Graduate Msn/dnp-level Advanced
Pharmacology
Q1.
A patient receiving warfarin for atrial fibrillation develops an acute exacerbation of heart
failure and is started on a loop diuretic and amiodarone. Which combination of
mechanisms best explains the anticipated rise in INR?
A. Amiodarone inhibits CYP2C9 and B. Amiodarone inhibits CYP2C9 and
displaces warfarin from albumin, while loop CYP3A4, and heart failure reduces hepatic
diuretics increase warfarin absorption. blood flow, reducing warfarin metabolism.
C. Loop diuretics induce CYP2C9, and D. Amiodarone induces CYP2C9, and heart
amiodarone increases vitamin K-dependent failure increases renal clearance of warfarin
clotting factor synthesis. metabolites.
Correct: B - Amiodarone inhibits CYP2C9 and CYP3A4, and heart failure reduces hepatic
blood flow, reducing warfarin metabolism.
Rationale:Amiodarone is a potent inhibitor of CYP2C9 (and CYP3A4), the major enzymes
metabolizing S-warfarin, and decompensated heart failure reduces hepatic perfusion, further
slowing warfarin clearance. Together these effects increase warfarin exposure and INR.
Options A, C, and D misstate enzyme effects, protein binding, or the direction of clearance
changes.
Q2.
A patient with type 2 diabetes and a history of heart failure with reduced ejection fraction
(HFrEF) needs intensified glycemic control. Which agent is most appropriate to add,
based on current cardiovascular outcome evidence?
A. Pioglitazone B. Saxagliptin
C. Empagliflozin D. Glyburide
Correct: C - Empagliflozin
Rationale:SGLT2 inhibitors such as empagliflozin reduce HF hospitalization and
cardiovascular death in patients with HFrEF and are recommended in current ADA/ACC/AHA
guidance. Pioglitazone causes fluid retention and can worsen heart failure; saxagliptin has
been associated with increased HF hospitalization; glyburide increases hypoglycemia risk
without HF benefit.
Page 3
, Section A - NURS 5334 Advanced Pharmacology 2 AND 2026/2027 AND 100 Detailed Rationales PASS Guaranteed A Advanced Pharmacology
Graduate Msn/dnp-level Advanced Pharmacology
Q3.
A patient with severe hepatic impairment (Child-Pugh C) requires treatment for a condition
for which a drug is normally hepatically metabolized. Which principle best guides dose
selection?
A. The maintenance dose should typically B. The loading dose should be reduced
be reduced, and the dosing interval may because hepatic impairment primarily
need to be extended because of reduced affects volume of distribution.
intrinsic clearance.
C. Renal excretion fully compensates, so no D. Protein binding increases, so free drug
adjustment is needed. concentration falls and the dose should be
increased.
Correct: A - The maintenance dose should typically be reduced, and the dosing interval
may need to be extended because of reduced intrinsic clearance.
Rationale:Hepatic impairment reduces intrinsic clearance of hepatically metabolized drugs,
so maintenance dosing usually requires dose reduction or interval extension. Loading dose is
generally unchanged unless volume of distribution is altered. Renal compensation is
incomplete, and hepatic impairment often decreases albumin and protein binding, increasing
free drug.
Q4.
Which statement best reflects the pharmacodynamic rationale for using a beta-1 selective
blocker rather than a nonselective beta blocker in a patient with asthma and coexisting
hypertension?
A. Beta-1 selectivity eliminates all B. Beta-1 selective blockers have greater
bronchoconstriction risk at any dose. efficacy for hypertension than nonselective
agents.
C. Beta-1 selective blockers reduce D. Nonselective beta blockers increase
blockade of pulmonary beta-2 receptors, renin release, worsening hypertension.
lowering bronchospasm risk at usual doses.
Correct: C - Beta-1 selective blockers reduce blockade of pulmonary beta-2 receptors,
lowering bronchospasm risk at usual doses.
Rationale:Beta-1 selective blockers such as metoprolol or atenolol preferentially block
cardiac beta-1 receptors, minimizing beta-2-mediated bronchoconstriction at usual doses,
though selectivity is dose-dependent. They are not more antihypertensive than nonselective
agents, and nonselective beta blockers decrease rather than increase renin release.
Q5.
A patient on lithium therapy presents with coarse tremor, ataxia, and confusion. Which set
of findings is most consistent with lithium toxicity and its management?
Page 4
PRACTICE 2026/2027 - QUESTIONS AND ANSWERS 100%
VERIFIED DETAILED RATIONALES - PASS GUARANTEED - A+
GRADED
148 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NURS 5334 ADVANCED PHARMACOLOGY EXAM 2 AND PRACTICE 2026/2027 - QUESTIONS AND
ANSWERS 100% VERIFIED DETAILED RATIONALES - PASS GUARANTEED - A+ GRADED. It contains 148
carefully selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 148 Questions
Foundations - Application - NURS 5334 Advanced Pharmacology 2 AND 2026/2027 AND 100 Detailed
Rationales PASS Guaranteed A Advanced Pharmacology Graduate Msn/dnp-level Advanced Pharmacology
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
NURS 5334 Advanced 1-25 Explains, Therapy, Chronic, Atrial Fibrillation, Heart Failure
Pharmacology 2 AND
2026/2027 AND 100 Detailed
Rationales PASS Guaranteed
A Advanced Pharmacology
Graduate Msn/dnp-level
Advanced Pharmacology
Mechanism 26-50 Explains, Appropriate, Monitoring, Inhibitors, Warfarin
Started 51-75 Explains, Mechanism, Prescribed, Develops, Property
Prescribed 76-100 Explains, Inhibitor, Pharmacodynamic, Asthma, Monitoring
Appropriate 101-125 Explains, Mechanism, Requires, Therapy, Describes
Failure 126-148 Mechanism, Explains, Heparin, Started, Reduced
TOTAL 148 All questions include answers and detailed rationales
,Section A - NURS 5334 Advanced Pharmacology 2 AND
2026/2027 AND 100 Detailed Rationales PASS Guaranteed A
Advanced Pharmacology Graduate Msn/dnp-level Advanced
Pharmacology
Q1.
A patient receiving warfarin for atrial fibrillation develops an acute exacerbation of heart
failure and is started on a loop diuretic and amiodarone. Which combination of
mechanisms best explains the anticipated rise in INR?
A. Amiodarone inhibits CYP2C9 and B. Amiodarone inhibits CYP2C9 and
displaces warfarin from albumin, while loop CYP3A4, and heart failure reduces hepatic
diuretics increase warfarin absorption. blood flow, reducing warfarin metabolism.
C. Loop diuretics induce CYP2C9, and D. Amiodarone induces CYP2C9, and heart
amiodarone increases vitamin K-dependent failure increases renal clearance of warfarin
clotting factor synthesis. metabolites.
Correct: B - Amiodarone inhibits CYP2C9 and CYP3A4, and heart failure reduces hepatic
blood flow, reducing warfarin metabolism.
Rationale:Amiodarone is a potent inhibitor of CYP2C9 (and CYP3A4), the major enzymes
metabolizing S-warfarin, and decompensated heart failure reduces hepatic perfusion, further
slowing warfarin clearance. Together these effects increase warfarin exposure and INR.
Options A, C, and D misstate enzyme effects, protein binding, or the direction of clearance
changes.
Q2.
A patient with type 2 diabetes and a history of heart failure with reduced ejection fraction
(HFrEF) needs intensified glycemic control. Which agent is most appropriate to add,
based on current cardiovascular outcome evidence?
A. Pioglitazone B. Saxagliptin
C. Empagliflozin D. Glyburide
Correct: C - Empagliflozin
Rationale:SGLT2 inhibitors such as empagliflozin reduce HF hospitalization and
cardiovascular death in patients with HFrEF and are recommended in current ADA/ACC/AHA
guidance. Pioglitazone causes fluid retention and can worsen heart failure; saxagliptin has
been associated with increased HF hospitalization; glyburide increases hypoglycemia risk
without HF benefit.
Page 3
, Section A - NURS 5334 Advanced Pharmacology 2 AND 2026/2027 AND 100 Detailed Rationales PASS Guaranteed A Advanced Pharmacology
Graduate Msn/dnp-level Advanced Pharmacology
Q3.
A patient with severe hepatic impairment (Child-Pugh C) requires treatment for a condition
for which a drug is normally hepatically metabolized. Which principle best guides dose
selection?
A. The maintenance dose should typically B. The loading dose should be reduced
be reduced, and the dosing interval may because hepatic impairment primarily
need to be extended because of reduced affects volume of distribution.
intrinsic clearance.
C. Renal excretion fully compensates, so no D. Protein binding increases, so free drug
adjustment is needed. concentration falls and the dose should be
increased.
Correct: A - The maintenance dose should typically be reduced, and the dosing interval
may need to be extended because of reduced intrinsic clearance.
Rationale:Hepatic impairment reduces intrinsic clearance of hepatically metabolized drugs,
so maintenance dosing usually requires dose reduction or interval extension. Loading dose is
generally unchanged unless volume of distribution is altered. Renal compensation is
incomplete, and hepatic impairment often decreases albumin and protein binding, increasing
free drug.
Q4.
Which statement best reflects the pharmacodynamic rationale for using a beta-1 selective
blocker rather than a nonselective beta blocker in a patient with asthma and coexisting
hypertension?
A. Beta-1 selectivity eliminates all B. Beta-1 selective blockers have greater
bronchoconstriction risk at any dose. efficacy for hypertension than nonselective
agents.
C. Beta-1 selective blockers reduce D. Nonselective beta blockers increase
blockade of pulmonary beta-2 receptors, renin release, worsening hypertension.
lowering bronchospasm risk at usual doses.
Correct: C - Beta-1 selective blockers reduce blockade of pulmonary beta-2 receptors,
lowering bronchospasm risk at usual doses.
Rationale:Beta-1 selective blockers such as metoprolol or atenolol preferentially block
cardiac beta-1 receptors, minimizing beta-2-mediated bronchoconstriction at usual doses,
though selectivity is dose-dependent. They are not more antihypertensive than nonselective
agents, and nonselective beta blockers decrease rather than increase renin release.
Q5.
A patient on lithium therapy presents with coarse tremor, ataxia, and confusion. Which set
of findings is most consistent with lithium toxicity and its management?
Page 4
